BJ
MCRB icon

BlackRock Japan’s Seres Therapeutics MCRB Stock Holding History

BlackRock Japan’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$6K Buy
29
+14
+93% +$3.05K ﹤0.01% 1249
2016
Q3 		$4K Buy
15
+4
+36% +$1.4K ﹤0.01% 1266
2016
Q2 		$6K Buy
+11
New +$6.45K ﹤0.01% 1334

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock Japan's MCRB Position: Q4 2016 in Review

BlackRock Japan increased its Seres Therapeutics (MCRB) stake by 93% in Q4 2016, buying an estimated $3.05K and bringing the position to 29 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1249.

BlackRock Japan first reported a position in MCRB in Q2 2016 and has held it in 3 quarters since. 89 funds tracked by Wall St. Rank hold MCRB as of Q4 2016.

  • BlackRock Japan held 29 shares of Seres Therapeutics worth $6K as of Q4 2016.
  • BlackRock Japan bought 14 Seres Therapeutics shares in Q4 2016, an estimated $3.05K.
  • Seres Therapeutics made up ﹤0.01% of BlackRock Japan's portfolio in Q4 2016, its #1249 holding.
  • BlackRock Japan first reported a position in Seres Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • 89 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2016.

Based on BlackRock Japan's 13F filing for Q4 2016, filed 10 Feb 2017.